Introduction
Pseudoseizures (''hysterical fits'') are a common clinical problem for family physicians, internists, psychiatrists, neurologists and neurosurgeons. Regrettably, the term ''pseudoseizure'' is firmly entrenched in the vernacular of modern clinical neurology. It is a word with significant psychological, social and clinical implications. From the patient's perspective, the diagnosis of pseudoseizures may result in diminished self-esteem, loss of insurance coverage, inappropriate medication adjustments, and strained interactions with members of the health care team. When a patient with history of pseudoseizures visits an emergency room, they are sometimes treated as ''fakers'', less deserving than people with ''true seizures''. To lessen the unfortunate connotations surrounding this diagnostic entity, various other terms have been introduced, including non-epileptic attack disorder (NEAD). 1 However, the much-needed destigmatization of pseudoseizures requires more than a change in nomenclature. It requires fundamental molecular level advances concerning the psychopharmacology of pseudoseizures as a behavioural disorder. Accordingly, medication effects in patients with pseudoseizures were studied. As part of this analysis, the novel concept of pseudoseizures as a possible medication-induced side-effect emerged.
Pseudoseizures are paroxysmal episodes of altered behaviour (movements, sensations) without concomitant seizure-associated electroencephalographic changes. 2 Although many have suggested that pseudoseizures are a cause of drug toxicity (as escalating doses are used in an attempt to suppress seemingly intractable spells), in this short communication the exact converse is argued: namely, that a sub-group of pseudoseizures may arise as an idiosyncratic toxic side-effect of anticonvulsants that are active at the gamma-aminobutyric acid (GABA-A) receptor. The term ''organic pseudoseizures'' is used to denote this group of medication related NEAD. To ascertain the significance of possible GABAergic-induced NEADs, a prospective study was performed correlating the occurrence of NEADs with the co-administration of GABAergic anticonvulsant agents.
Methods and results
Of 352 consecutive patients evaluated in the Kingston General Hospital Epilepsy Clinic during the first 8 months of 1999, 56 (16%) had pseudoseizures, either in isolation or in association with seizures. Of these 56 patients, 5 (9%) had pseudoseizures that had commenced concomitantly (within 14-29 days) with the administration of specific GABAergic anticonvulsant agents (e.g. clobazam [1/5] , clonazepam [1/5] , primidone [1/5] , vigabatrin [2/5] ) and which had resolved following discontinuation of the medication (within 18-37 days); these pseudoseizures were superimposed upon an underlying seizure disorder of greater than 4 years duration without previous documentation of non-epileptic attacks. All five affected individuals had a pre-existing diagnosis of complex-partial seizures. An additional 12/56 patients in the pseudoseizure group were also receiving one or more of these four GABAergic agents, but with no time correlation between the administration of the agent and the onset of the non-epileptic attacks. The administration of carbamazepine, phenytoin, valproate, or lamotrigine was not associated with the initiation of non-epileptic attacks in any patient seen during the study period.
Discussion
Pseudoseizures have a poorly defined epidemiology, reflecting difficulties in establishing their prevalence and incidence. Various estimates suggest that 9-24% of patients being evaluated for epileptic seizures actually have pseudoseizures; thus, pseudoseizures are a significant health care problem. 1 Although concepts concerning the aetiology of pseudoseizures are still in evolution, psychological explanations currently predominate, with pseudoseizures being regarded as a learned pattern of behaviour developed to enable a person to deal with environmental stressors. 3 Gates, however, recognized the heterogeneity of pseudoseizures, categorizing non-epileptic spells as either physiologic (e.g. parasomnias) or psychological (e.g. depression, conversion disorder). 4, 5 To this classification system, the present study offers a new category: pharmacologic. Five patients with no pre-existing psychopathology were identified. All five patients developed pseudoseizures concomitant with the introduction of a GABAergic anticonvulsant drug; all had abatement of the pseudoseizures following discontinuation of the agent. None had previously experienced pseudoseizures; none had further pseudoseizures in 24 months of follow-up. Thus, there was a definite correlation between the duration of pseudoseizure susceptibility and the administration of a GABAergic agent.
The observations of this study suggest that GABAergic anticonvulsants may produce non-epileptic attacks as a side-effect. Of the traditional anticonvulsants, primidone and phenobarbital are prototypic GABAergic agents. The barbiturate mechanism of action is via prolonged chloride channel opening at the GABA-A receptor complex. The capacity of barbiturates to produce behavioural side-effects has been well documented, producing emotional outbursts, significant depression and personality changes in both children and adults. Benzodiazepines (clonazepam, clobazam) are also GABAergic agents, binding to the GABA-A receptor and increasing the rate of ion channel opening frequency. Irritability and aggressiveness have all been documented as side-effects of benzodiazepine administration. Among the new anticonvulsants, vigabatrin is an agent with significant GABAergic properties via irreversible inhibition of the GABA transaminase enzyme, leading to increased GABA levels. Over the past decade the ability of vigabatrin to elicit psychiatric reactions has been noted. 6 Depression, confusion and other behavioural abnormalities also accompany vigabatrin use. (In addition, GABAergic processes may also play a role in other neuropsychiatric disorders, including Huntington's Disease, and schizophrenia. 7 ) Therefore, neurochemical evidence suggests a capacity for GABAergic agents to produce behavioural side-effects.
Other authors have suggested the possibility of anticonvulsant-induced episodic behavioural disorders. For example, Rabe described a patient in whom anticonvulsant medication led to the ''initiation of hysterical fits''. 8 He concluded that there was a mutual antagonism between seizures and psychiatric problems and that as the seizures improved, the psychiatric problem emerged. Neidermeyer et al. also suggested that pseudoseizures may be enhanced by anticonvulsants. 9, 10 He postulated that pre-existing ''cerebral dysfunction'' predispose certain individuals to exhibit pseudoseizures and that diffuse electroencephalographic slow wave activity arising from anticonvulsant toxicity facilitates the expression of pseudoseizures. Neither Rabe nor Neidermeyer restricted the side-effect to a particular anticonvulsant drug.
Conclusions
In conclusion, the existence of ''organic pseudoseizures'' as a reversible drug-induced side-effect has been identified. Barbiturates, benzodiazepines and vigabatrin produce behavioural side-effects; pseudoseizures are a behavioural problem. Extending the conclusions of this study to other agents (e.g. tiagabine) is not within the scope of the available data. Since patients with complex partial epilepsy are usually on multiple medications with frequent medication adjustments, time linked relationships between the onset of pseudoseizures and the administration of a particular anticonvulsant agent may go unrecognized. Nevertheless, the identification of drug-induced organic pseudoseizures is a significant observation that is important to the management of patients presenting with atypical spells suggestive of non-epileptic seizures.
